Mark Kieran
About Mark Kieran
Mark Kieran serves as the Vice President of Clinical Development at Day One Biopharmaceuticals, focusing on pediatric oncology. He has extensive academic and industry experience, including leadership roles at Bristol Myers Squibb and Dana-Farber Cancer Institute.
Work at Day One Biopharmaceuticals
Mark Kieran serves as the Vice President of Clinical Development at Day One Biopharmaceuticals, a company focused on pediatric oncology. He joined the organization in July 2021, bringing extensive experience in clinical development. His role involves leading initiatives aimed at advancing treatment options for pediatric patients with cancer. Under his leadership, the company aims to enhance its clinical programs and drive innovation in the field of pediatric oncology.
Current Role at Bristol Myers Squibb
Prior to his position at Day One Biopharmaceuticals, Mark Kieran worked at Bristol Myers Squibb as a Pediatric Clinical Trial Lead since 2018. In this role, he focused on pediatric oncology initiatives, particularly emphasizing combination therapies. His expertise in regulatory oversight and medical affairs contributed to the foundation for product commercialization within the company.
Education and Expertise
Mark Kieran has a robust educational background in medicine and related fields. He earned his Doctor of Medicine (MD) from the University of Calgary, School of Medicine. He also holds a Doctor of Philosophy (PhD) in Immunology from the University of Alberta. His postdoctoral studies include a fellowship in Molecular Biology at the Pasteur Institute and a fellowship in Signal Transduction at Harvard Medical School - Boston Children's Hospital. Additionally, he completed a Pediatric residency at McGill University and a Pediatric Hematology/Oncology Fellowship at Harvard Medical School.
Background in Pediatric Neuro-Oncology
Mark Kieran developed and led a multi-disciplinary program in pediatric neuro-oncology at the Dana-Farber Cancer Institute. This program integrated various clinical and laboratory efforts, establishing a reputation for excellence in the field. His transition from academia to industry in 2018 was motivated by a desire to focus on pediatric oncology initiatives, which he has continued to pursue in his current roles.